Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

被引：5
|
作者：
Ipp, Eli [1 ]
Genter, Pauline [2 ]
Childress, Kristin [1 ]
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[2] Los Angeles Biomed Res Inst, Torrance, CA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 09期
关键词：
RETINOPATHY; PROGRESSION;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：890 / 891
页数：2
相关论文
共 50 条
  • [1] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [2] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Husain, Mansoor
    Birkenfeld, Andreas L.
    Donsmark, Morten
    Dungan, Kathleen
    Eliaschewitz, Freddy G.
    Franco, Denise R.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Mosenzon, Ofri
    Pedersen, Sue D.
    Tack, Cees J.
    Thomsen, Mette
    Vilsboll, Tina
    Warren, Mark L.
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09): : 841 - 851
  • [3] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [4] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes reply
    Husain, Mansoor
    Donsmark, Morten
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2076 - 2077
  • [5] Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes
    Marso
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 159 - 159
  • [6] Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    McGuire, D. K.
    Marx, N.
    Mulvagh, S. L.
    Deanfield, J. E.
    Inzucchi, S. E.
    Pop-Busui, R.
    Mann, J. F. E.
    Emerson, S. S.
    Poulter, N. R.
    Engelmann, M. D. M.
    Ripa, M. S.
    Hovingh, G. K.
    Brown-Frandsen, K.
    Bain, S. C.
    Cavender, M. A.
    Gislum, M.
    David, J-P
    Buse, J. B.
    SOUL Study Group
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [7] Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
    Mahaffey, Kenneth W.
    Tuttle, Katherine R.
    Arici, Mustafa
    Baeres, Florian M. M.
    Bakris, George
    Charytan, David M.
    Cherney, David Z., I
    Chernin, Gil
    Correa-Rotter, Ricardo
    Gumprecht, Janusz
    Idorn, Thomas
    Pugliese, Giuseppe
    Rasmussen, Ida Kirstine Bull
    Rasmussen, Soren
    Rossing, Peter
    Sokareva, Ekaterina
    Mann, Johannes F. E.
    Perkovic, Vlado
    Pratley, Richard
    EUROPEAN HEART JOURNAL, 2024,
  • [8] Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
    Thethi, Tina K.
    Pratley, Richard
    Meier, Juris J.
    DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1263 - 1277
  • [9] Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes
    Temporelli, Pier Luigi
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2025, 27 : i1 - i5
  • [10] Semaglutide and cardiovascular outcomes in obesity without diabetes
    Basolo, A.
    Fierabracci, P.
    Salvetti, G.
    Santini, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (05) : 1047 - 1049
12345